Drugs May Transform Hepatitis C Treatment
April 1, 2011
Two experimental therapies could revolutionize hepatitis C virus (HCV) treatment, experts said Wednesday. The new drugs also reportedly reduce disparities in treatment response rates between black HCV patients and white HCV patients.
In a study of 1,097 treatment-naïve patients with HCV genotype 1, all were given standard therapy for the first four weeks. One-third then continued on that treatment, while two-thirds were given standard therapy in combination with different regimens of boceprevir. The boceprevir arms had SVRs of 63 percent and 66 percent, compared with 38 percent SVR for conventional treatment. In a second study involving 403 patients who had failed therapy or experienced a relapse, the boceprevir arms achieved 59 percent and 66 percent SVRs, compared with 21 percent on standard therapy.
Similar results for telaprevir were expected to be presented Thursday at a gathering of liver researchers in Berlin.
The two boceprevir studies, "Boceprevir for Untreated Chronic HCV Genotype 1 Infection" and "Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection," were published in the New England Journal of Medicine (2011;364:1195-1206 and 1207-1217, respectively).
Los Angeles Times
03.31.2011; Thomas H. Maugh II
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)